Probiotic Screening and Preclinical Research Services for Hyperuricemia

Creative Biolabs provides hyperuricemia probiotic screening and preclinical efficacy services to help development teams determine whether candidate strains affect urate through purine degradation, altered urate handling, or host metabolic and inflammatory pathways. We combine strain-level assays, disease-relevant animal models, microbiome profiling, and functional endpoints into decision-ready evidence for program advancement.

Advancing Urate-Lowering Probiotic Research with Mechanistic Evidence

Elevated serum urate is linked to gout and metabolic or renal complications, but probiotic development programs need evidence beyond a decrease in circulating urate. Candidate strains may differ in purine handling, intestinal microbial metabolism, host urate transport, or inflammatory responses. Without an assay strategy that separates these pathways, promising animal findings can be difficult to interpret and reproduce.

For metabolic-disease biotechnology teams, probiotic developers, and functional-food research groups, a robust preclinical plan connects strain activity to an appropriate disease model and measurable biological outcomes. Creative Biolabs supports this progression through focused functional screening, microbiome analysis, metabolic efficacy testing, and coordinated endpoint evaluation that informs whether a candidate merits further investigation.

Purine and urate turnover

Follow substrate conversion and production enzymes rather than assuming that serum changes prove bacterial degradation.

Intestinal and renal handling

Study candidate effects on epithelial or kidney-associated transport pathways in a fit-for-purpose model.

Microbiome and host response

Interpret SCFAs, community shifts and inflammation as mechanistic context alongside direct efficacy measurements.

Our Hyperuricemia Probiotic Screening and Preclinical Research Services

From strain screening to mechanism and metabolic efficacy, our modules are organized around the development questions that determine whether a probiotic candidate is worth advancing.

Urate and Purine Degradation Screening

We screen candidate probiotics for the transformation of purine nucleosides and urate-related substrates under controlled in vitro conditions. Assays distinguish nucleoside depletion, intermediate formation and possible urate removal from nonspecific adsorption or medium effects. Time-course LC-based or complementary analytical readouts support strain ranking, while viability and growth controls help establish whether activity is biologically reproducible.

Decision output: a prioritized candidate shortlist with conversion curves, controls and feasibility flags.

Urate Production and Transport Mechanism Studies

To distinguish reduced urate synthesis from altered handling, we investigate xanthine oxidase (XOD), adenosine deaminase (ADA), selected transporter targets such as ABCG2, URAT1 and GLUT9, and relevant tissue-specific pathways. Transcriptional measurements can be complemented by enzyme activity assays and protein-level measurements, with each matrix and assay selected for the tissue and biological question.

Decision output: a pathway-level mechanism hypothesis with orthogonal confirmatory endpoints.

Hyperuricemia Dose–Response and Time-Course Studies

We establish candidate-specific exposure schedules and serial sampling plans to determine whether urate-related responses are consistent, dose-dependent and sustained. Appropriate comparator groups, baseline measurements and serial serum urate assessments help distinguish a transient laboratory finding from reproducible biological activity in a selected preclinical system.

Decision output: dose-selection evidence, temporal response profiles and clear criteria for candidate advancement.

Kidney Protection and Inflammation Profiling

Serum creatinine, blood urea nitrogen, renal histology and kidney-associated transport markers are evaluated alongside systemic or tissue inflammatory endpoints. Where justified by the model, probiotic anti-inflammatory assays examine IL-1β, IL-6, TNF-α and related readouts, separating potential anti-inflammatory activity from direct urate metabolism effects.

Decision output: renal and inflammatory safety-context evidence with a clear interpretation of limitations.

Gut Microbial Community and Candidate Tracking

We characterize microbiota changes associated with candidate administration using 16S rRNA sequencing and focused microbial quantification. Baseline-to-follow-up comparisons can identify shifts in community structure, candidate persistence and potential associations with host urate endpoints, without treating microbial correlations alone as proof of causality.

Decision output: strain and community response profiles that support interpretation of the primary efficacy findings.

Dose, Viability and Development Readiness

Candidate advancement also depends on viable dose, reproducible preparation and tolerability over time. We support exploratory dose-range plans, repeated-dose observations and batch consistency discussions, with small-scale probiotic production and stability-oriented sample preparation as relevant. The resulting plan distinguishes demonstrated evidence from studies still required before further development.

Decision output: a dose-and-quality decision matrix, batch records and next-study recommendations.

Services may be scoped individually or combined into a staged preclinical package. Candidate-specific study methods, matrices and study duration are defined during project design.

Research Candidates and Microbiome Assay Strategies

Strain-level evidence, not species-wide assumptions

Published hyperuricemia models have explored Lacticaseibacillus rhamnosus 1155, Limosilactobacillus fermentum 2644 and Lactiplantibacillus plantarum TCI227, among other candidates. These results justify strain-specific functional questions; they do not establish that every member of the same species produces the same urate-related effects.

A recent study of Lactobacillus paracasei N1115 also illustrates the value of connecting urate-related serum chemistry with kidney markers, inflammatory endpoints and gut microbial metabolites. All such observations require study-specific interpretation and independent confirmation before broader claims.

Analytical capabilities tailored to the hypothesis

Our Hyperuricemia Probiotic Preclinical Study Workflow

A sequential, hypothesis-driven process that moves from controlled strain characterization to interpretable animal and mechanistic evidence.

1

Scope the hypothesis

Set the strain, model, urate pathway, matrix and primary success criteria before testing.

2

Screen and verify

Confirm identity, viable dose and functional activity with appropriate negative controls.

3

Establish efficacy

Run a fit-for-purpose hyperuricemia model with dose, sampling and comparison groups.

4

Interrogate mechanisms

Combine urate enzymes, renal markers, inflammatory signals and microbiome metabolites.

5

Synthesize decisions

Integrate evidence, flag limitations and propose the next confirmation or development study.

Hyperuricemia Preclinical Study Readouts and Deliverables

The panel below illustrates how each research question is converted into a measurable endpoint and practical program decision. Final assay selection depends on the candidate, study stage and model.

Research question Representative study readouts Client deliverables and decision value
Does serum urate change? Serum uric acid over time, exposure duration, dose groups and appropriate controls. Primary efficacy comparison with effect sizes, variability and reproducibility checks.
Which mechanism is plausible? Purine substrate conversion, XOD/ADA activity, selected ABCG2/URAT1/GLUT9 pathways. Mechanistic evidence map distinguishing degradation, synthesis and transport effects.
What happens to renal function? Blood urea nitrogen, serum creatinine, renal histology and kidney-associated molecular markers. Renal response and tolerability summary, with interpretation boundaries.
Is the microbiome involved? 16S rRNA community profiles, qPCR-selected targets, fecal acetate, propionate and butyrate. Integrated microbial and metabolite report identifying candidate explanatory associations.
Can the candidate advance? Viable dose, batch consistency, repeated-dose observations and planned stability checks. Research-ready data package and prioritized recommendations for next-stage confirmation.

Published Data on Probiotic Regulation of Uric Acid Metabolism

Recent research in a peer-reviewed hyperuricemia mouse model evaluated Lactobacillus paracasei N1115 across serum urate, renal biochemical indices, enzymes involved in urate production, inflammatory factors and fecal short-chain fatty acids. Compared with untreated hyperuricemic mice, intervention groups showed lower serum urate and changes in several associated biomarkers. The study underscores why preclinical evaluation benefits from measuring urate metabolism and host physiology together, rather than relying on serum urate alone.

The published data also provide a useful framework for selecting orthogonal endpoints: xanthine oxidase and adenosine deaminase for urate production, kidney chemistry and transport-related markers for excretion pathways, and microbial metabolites for gut-associated mechanisms. Creative Biolabs can help research teams translate these questions into strain-specific screening, coordinated animal-model studies and integrated endpoint reports. These findings are preclinical, and their implications should not be generalized across probiotic strains or presented as demonstrated human clinical efficacy.

Serum urate, renal chemistry, inflammatory cytokine and fecal short-chain fatty acid measurements after L. paracasei N1115 intervention. (OA Literature)
Fig.1 L. paracasei N1115 regulated UA metabolism and SCFAs. 1,4

Why Choose Creative Biolabs for Hyperuricemia Probiotic Research?

Mechanism-First Study Design

Urate degradation, synthesis and excretion are treated as competing hypotheses with distinct assay plans.

Strain-Level Interpretation

Candidate identity, dose and viability are tracked so strain-specific biology is not generalized.

Fit-for-Purpose Models

Metabolic and renal readouts are selected to match the stage and questions of each research program.

Integrated Data Packages

Biochemical, microbiota and inflammatory endpoints are interpreted together with transparent controls.

Traceable Methods and QC

Sampling, batch history and assay conditions are organized for repeatability and partner review.

Decision-Oriented Reporting

Deliverables distinguish supported findings, associative signals, uncertainty and recommended next steps.

Recommended Services for Advanced Hyperuricemia Research

These complementary capabilities can support deeper mechanism-of-action analysis and targeted metabolic evaluation when the core research design calls for additional data.

Build an Evidence-Based Hyperuricemia Research Plan

Share your candidate strain, preliminary data and study goals. We can help scope a practical sequence of screening, mechanism and preclinical efficacy assessments.

Frequently Asked Questions

We combine substrate-conversion assays and metabolite mass balance with serum urate, renal transporter and excretion-related endpoints. A drop in serum urate alone cannot identify the responsible pathway; orthogonal evidence and appropriate model controls are needed.

A common primary endpoint is serum urate, supported by renal chemistry such as creatinine and blood urea nitrogen, urate-metabolizing enzyme activity, tissue histology and selected transporter markers. Inflammatory and microbiome measures can provide mechanistic support but should not replace a direct efficacy readout.

Yes. Sampling schedules can pair microbial community profiles and fecal short-chain fatty acids with serum urate, renal and inflammatory measurements. Association is interpreted cautiously; additional perturbation or targeted assays may be required before making causal claims.

Exploratory dose-ranging and repeated-dose designs can include body weight, food intake, general health, renal and hepatic chemistry, and microbiological checks. Viability and batch consistency can be reviewed alongside formulation and storage conditions; study duration is selected according to the intended development stage.

An initial discussion is most productive with the candidate strain information, available identity or genomic data, intended use, preliminary urate-related findings, preferred model and the decision you want the study to support. We then propose endpoints, sample needs and a staged work plan.

References

  1. Zhang, Hongyu, et al. "Lactobacillus paracasei N1115 alleviates hyperuricemia in mice: regulation of uric acid metabolism as well as its impact on gut microbiota and short-chain fatty acids." Frontiers in Nutrition 12 (2025): 1651214. https://doi.org/10.3389/fnut.2025.1651214
  2. Li, Yanjun, et al. "Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats." Frontiers in Nutrition 9 (2022): 993951. https://doi.org/10.3389/fnut.2022.993951
  3. Chien, Chih-Yu, et al. "Supplementation of Lactobacillus plantarum (TCI227) prevented potassium-oxonate-induced hyperuricemia in rats." Nutrients 14.22 (2022): 4832. https://doi.org/10.3390/nu14224832
  4. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket
Close